|The full article is available to subscribers||Subscriber Login|
The FDA has approved crisaborole 2% ointment (Eucrisa – Pfizer) for topical treatment of mild to moderate atopic dermatitis in patients ≥2 years old. It is the first phosphodiesterase type-4 (PDE4) inhibitor to be approved in the US for this indication.
ATOPIC DERMATITIS — Atopic dermatitis (also known as atopic eczema) is a chronic pruritic inflammatory skin disease that commonly presents in infancy or early childhood and is frequently associated with other atopic disorders such as allergic rhinitis and asthma. It has a relapsing course, often improving by adolescence. In infants, atopic dermatitis typically involves the face, scalp, and extensor surfaces of the limbs. In older patients, it characteristically involves the flexural areas.
STANDARD TREATMENT — Application of moisturizers, emollients, and barrier creams can reduce the need for pharmacologic therapy.... more
- LF Eichenfield et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71:116.
- Drugs for allergic disorders. Treat Guidel Med Lett 2013; 11:43.
- WW Carr. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 2013; 15:303.
- K Jarnagin et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol 2016; 15:390.
- LT Zane et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol 2016; 33:380.
- AS Paller et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75:494.